CYCLONE3
12 Apr 2022
CYCLONE 3
NCT05288166
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Eli Lilly and Company
Cancer Type | Prostate |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Male |
Tumour Stream | - |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | 2022-04-01 |
Anticipated End Date | 2027-10-01 |
Hospital | Icon Cancer Centre Adelaide |
---|---|
Clinical Trial Coordinator | Sue Yeend |
sue.yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Dr Francis Parnis |
Recruitment Status | Not Yet Recruiting |
Keep up to date with the latest news and breakthroughs